重症肺炎免疫调节治疗:决定临床结局的双刃剑
重症肺炎尤其进展为感染中毒症的患者存在免疫失衡,免疫调节治疗临床证据矛盾:同类药物结局不同,作用相反药物结局相似。异质性可能源于宿主基线状态、病原类型、病程阶段及治疗时机的动态差异。未来需构建精准免疫评估体系,结合动态生物标记物、代谢调控和AI辅助决策,实现个体化时序治疗。
要点
- 重症肺炎核心病生理为免疫失衡,免疫调节治疗证据矛盾。
- 异质性源于宿主基线、病原、病程及治疗时机差异。
- 精准免疫评估需整合动态标志物、代谢调控与AI决策。
核心结论
- 免疫调节治疗在重症肺炎中呈双刃剑效应,需精准免疫评估实现个体化时序治疗。
主要发现
- 靶向相似通路的药物可能产生不同结局,作用相反的药物可能出现相似结局。
临床怎么用
- 结合动态生物标志物检测、代谢调控和AI辅助决策,推动免疫调节治疗从经验走向精准医学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe pneumonia remains a major threat to human health, particularly in patients who progress to sepsis, with immune dysregulation playing a central role in its pathophysiological mechanism. Although immunomodulatory therapies have evolved alongside our improved understanding of immune imbalance, conflicting clinical evidence persists. For example, agents targeting similar pathways may produce divergent outcomes, while those with opposing mechanisms of action may yield comparable results. This heterogeneity likely stems from dynamic variations in the host's baseline status, pathogen type, disease stage, and therapeutic timing. Future breakthroughs will require a framework for precision immune profiling that integrates dynamic biomarker monitoring, metabolic modulation, and AI-assisted decision-making. The aim of such strategies is to achieve therapy that is tailored to the individual patient, optimized over time, and balances pathological suppression with host defense preservation. This will advance immunomodulatory therapies from empirical approaches to precision medicine paradigms. 重症肺炎是人类健康的重要威胁,尤其是进展为感染中毒症的患者,其核心病生理机制是免疫失衡。免疫调节治疗随着学界对免疫失衡认知加深而进步,但临床研究结果矛盾频现:同类药物可能产生不同结局,而作用相反的药物可能出现相似结局的。这种异质性可能源于宿主基线状态、病原类型、病程阶段及治疗时机的动态差异等相关。未来突破需聚焦精准免疫评估体系构建,结合动态生物标记物检测、代谢调控和AI辅助决策,实现个体化时序治疗,在抑制病理损伤与保留宿主防御间达成平衡,推动免疫治疗的精准狙击。.
引用
- Weng JZ, Li YM. [Immunomodulatory therapy in severe pneumonia: a double-edged sword in determining clinical outcomes]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40925730. doi:10.3760/cma.j.cn112147-20250505-00247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。